Skip to main content

Table 1 Overview of the diagnosis, duration of CME, and ocular and systemic treatment of the patients prior to FAc implant

From: Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema

No. of eye Gender, age (years) Diagnosis Systemic treatment Duration of chronic ME under therapy Previous ocular treatments
1 OD/OS M, 60 Panuveitis, rheumatoid arthritis Cyclosporine, methotrexate, prednisolone 36 months Multiple triamcinolone periocular, multiple dexamethasone intravitreal
2 OS M, 50 Intermediate uveitis Mycophenolate 36 months Multiple triamcinolone periocular and subconjunctival, multiple dexamethasone intravitreal
3 OS F, 25 Posterior uveitis, acute zonal outer occult retinopathy (AZOOR) None currently, previously mycophenolate (stopped because of intolerances) 6 years Multiple dexamethasone intravitreal, bevacizumab (1×) intravitreal
4 OD/OS F, 48 Intermediate uveitis None currently, previously methotrexate and mycophenolate, (mycophenolate stopped when diagnosed with malignant melanoma) 4 years Multiple triamcinolone periocular and intravitreal, multiple dexamethasone intravitreal
5 OD/OS F, 45 Posterior uveitis, multifocal chorioretinitis and panuveitis (MCP) Azathioprine 6 years Multiple triamcinolone periocular and intravitreal, multiple dexamethasone intravitreal
6 OD M, 50 Intermediate uveitis, multiple sclerosis Previously: high-dose corticosteroid therapy, interferon beta, fingolimod
Currently: rituximab IV every 6 to 9 months
18 months Triamcinolone periocular (2×), dexamethasone intravitreal (2×)
7 OD F, 37 Intermediate uveitis Cyclosporine, methotrexate 9 years Multiple triamcinolone subconjunctival, multiple dexamethasone intravitreal
8 OD F, 65 Idiopathic vasculitis None 25 months Triamcinolone periocular (1×), multiple dexamethasone intravitreal (3×)